Electroacupuncture combined with biofeedback for obstructed defecation syndrome: a retrospective cohort study Authors: Liu Wenhui, Tang Kun, Li Ming, Li Siyuan, Zhou Qiubing Published: 2026 ABSTRACT AbstractObjectiveTo investigate the therapeutic efficacy of electroacupuncture combined with biofeedback therapy (BFT) in patients with obstructed defecation syndrome (ODS).MethodsThis single-center retrospective cohort study included 296 patients with ODS, who were assigned to either a BFT group (n = 112) or an electroacupuncture plus BFT group (n = 184) according to the treatment modality received. “Post-treatment” outcomes were operationally defined as assessments performed after completion of the 10th BFT session and before initiation of the 11th session. The primary outcome was the responder rate based on mean weekly complete spontaneous bowel movements (CSBMs). Secondary outcomes included the Constipation Scoring System (CSS), Traditional Chinese Medicine (TCM) syndrome score for constipation, quality of life assessed by the Patient Assessment of Constipation Quality of Life questionnaire (PAC-QOL), and pelvic floor surface electromyography (sEMG) parameters. Clinical efficacy grade was determined according to the TCM syndrome therapeutic efficacy evaluation criteria.ResultsBaseline characteristics were comparable between the two groups (P > 0.05). The overall response rate was significantly higher in the electroacupuncture plus BFT group than in the BFT group (90.76% [167/184] vs. 80.36% [90/112], P < 0.05). Weekly CSBM responder rate was also significantly higher in the combination group (90.8% vs. 69.6%, P < 0.05). After treatment, both groups showed significant improvements in mean weekly CSBM per patient, mean weekly laxative use days, CSS scores, TCM syndrome score for constipation, PAC-QOL scores, and pelvic floor sEMG parameters compared with baseline (all P < 0.01). Improvements in TCM syndrome score for constipation, the coefficient of variation of the pre-resting baseline, post–rapid contraction relaxation time, and endurance contraction coefficient of variation were significantly greater in the combination group than in the BFT group (P < 0.05). Female patients showed smaller improvement in PAC-QOL scores than male patients (β = 4.403, P = 0.004). In the multivariable ordinal model, treatment modality was associated with higher efficacy grades, whereas laxative use during the treatment period was associated with lower efficacy grades (both P < 0.001). In addition, disease duration was positively correlated with improvements in CSS scores.ConclusionsElectroacupuncture combined with BFT is more effective than BFT alone in alleviating defecatory difficulty and improving quality of life in patients with ODS, suggesting that this combined approach has favorable clinical applicability.Supplementary InformationThe online version contains supplementary material available at 10.1007/s00384-026-05127-5.Keywords: Obstructed defecation syndrome, Electroacupuncture, Biofeedback therapy, Retrospective cohort study Background In recent years, with changes in lifestyle and the acceleration of population aging, the prevalence of chronic functional constipation has shown a steady upward trend. Recent epidemiological studies indicate that the global prevalence of functional constipation among adults ranges from 10.1 to 15.3% [1, 2]. Population-based studies have further demonstrated that the prevalence is higher among women, older individuals, and those with lower socioeconomic status and increases progressively with advancing age [3, 4]. Constipation not only significantly impairs patients’ quality of life but is also frequently accompanied by psychological comorbidities such as anxiety and depression, thereby imposing a substantial burden on both society and healthcare systems [5]. Among the subtypes of functional constipation, obstructed defecation syndrome (ODS) represents a major clinical entity. It is characterized by impaired rectal evacuation leading to secondary constipation, with core symptoms including excessive straining, a sensation of incomplete evacuation, and the need for manual assistance during defecation, all of which markedly reduce patients’ quality of life [6]. It has been reported that approximately 30–50% of patients with chronic constipation exhibit varying degrees of outlet obstruction [7, 8]. The pathophysiology of obstructed defecation syndrome is complex, involving both structural abnormalities, such as rectocele, internal rectal intussusception, and rectal mucosal prolapse, and functional disorders, including pelvic floor dyssynergia and sphincter spasm [9]. Owing to its heterogeneous etiologies, conventional therapeutic approaches often yield suboptimal outcomes, with relatively high recurrence rates. At present, multidisciplinary consensus statements generally recommend biofeedback therapy (BFT) as the main non-surgical treatment for ODS. BFT facilitates patients’ acquisition of appropriate defecatory patterns through visual and auditory feedback, thereby promoting coordinated activation of the pelvic floor musculature and improving defecatory function. Previous studies have reported clinical response rates of approximately 60–80% [10]. Short-term studies have demonstrated that BFT can effectively alleviate defecatory symptoms and improve anorectal physiological parameters [11], while long-term follow-up data suggest that therapeutic benefits can be sustained in a substantial proportion of patients [12]. In addition, BFT has been shown to improve sleep quality and psychological well-being in patients with concomitant insomnia or emotional disorders, leading to an overall enhancement in quality of life [13]. Nevertheless, the onset of therapeutic effects with BFT alone is relatively slow, and patient adherence and long-term compliance are frequently suboptimal. In recent years, increasing attention has been directed toward combining BFT with other therapeutic modalities. Emad et al. conducted a randomized controlled trial comparing BFT with botulinum toxin type A (BTX-A) injection and found that both interventions were effective for ODS; however, BFT was superior in improving short-term constipation symptoms, whereas BTX-A injection was more favorable for restoring anorectal physiological function. These findings suggest that combination strategies may represent a promising direction for optimizing treatment efficacy [14]. With the advancement of neuromodulation techniques, various electrical stimulation modalities, including electroacupuncture, transcutaneous electrical nerve stimulation (TENS), and transanal/rectal electrical stimulation (R-ES), have been increasingly applied in the clinical management of pelvic floor dysfunction disorders [15–17]. In patients with hyposensitive constipation, electrical stimulation combined with biofeedback therapy has been shown to significantly improve defecatory urge, rectal sensory thresholds, and overall clinical symptoms compared with BFT alone, suggesting a synergistic therapeutic effect [18]. Furthermore, multiple clinical studies have demonstrated that electroacupuncture combined with BFT is more effective in alleviating defecatory difficulty and improving anorectal motility parameters in patients with ODS than either intervention alone [19, 20]. Experimental studies have suggested that electroacupuncture exerts its therapeutic effects through modulation of neural pathways along the gut–brain axis, thereby improving colorectal sensory function and neuromuscular coordination of the pelvic floor [21, 22]. Human neuroimaging studies further indicate that acupuncture can selectively regulate brain regions involved in visceral sensation and motor control, including the anterior cingulate cortex, insula, and somatosensory cortex, enhancing the processing of rectal distension signals and facilitating coordinated defecation [23]. In addition, electroacupuncture has been reported to directly improve colonic motor function by modulating high-amplitude propagating contractions (HAPCs) and enteric nervous system (ENS) activity [24]. In traditional Chinese medicine, functional constipation is conceptually classified as “difficulty in defecation” (Runchang) in Traditional Chinese Medicine (TCM); however, from a modern biomedical perspective, obstructed defecation is primarily characterized by impaired colorectal sensory–motor integration and dysregulated pelvic floor coordination. In the present study, ST25 (Tianshu), ST36 (Zusanli), BL33 (Zhongliao), and BL34 (Xialiao) were selected as the main stimulation sites based on their anatomical locations and potential neuromodulatory effects. ST25 and ST36 are located in the abdominal region, which is innervated by thoracolumbar segments and are closely associated with autonomic regulation of gastrointestinal motility. Previous studies have demonstrated that stimulation at these sites can modulate serum levels of vasoactive intestinal peptide, motilin, and serotonin, thereby facilitating gastrointestinal transit and functional recovery [25]. BL33 and BL34 correspond anatomically to the sacral nerve root exit zones. Electrical stimulation in this region can directly modulate sacral nerve activity and improve neuromuscular control of the pelvic floor and levator ani muscles, alleviating paradoxical anal sphincter contraction and insufficient relaxation of the puborectalis muscle during defecation [26]. Previous studies have further confirmed that sacral electrostimulation at the Baliao region enhances rectal evacuation efficiency and improves anorectal manometric parameters in patients with functional constipation [27]. In this study, abdominal and sacral stimulation sites were alternated on different days to minimize local habituation and maintain a stable stimulation threshold. Alternating activation of different neural segments may contribute to sustained modulation of intestinal motility and coordinated pelvic floor function. Therefore, this retrospective cohort study is aimed at comparing the effectiveness of electroacupuncture combined with biofeedback therapy versus biofeedback therapy alone in patients with obstructed defecation syndrome, and we hypothesized that the combined therapy would result in greater improvements in bowel symptoms, quality of life, and pelvic floor surface electromyography parameters. Methods Study design and study population This study was designed as a single-center retrospective cohort study. We retrospectively reviewed the medical records of 296 patients diagnosed with obstructed defecation syndrome (ODS) at the Department of Colorectal Surgery, The First Affiliated Hospital of Anhui University of Chinese Medicine, between January 2021 and January 2025. The diagnosis of ODS was established based on the results of colonic transit tests, anorectal manometry, anal electromyography, and defecography. All patients met the diagnostic criteria for ODS according to the Rome IV classification [28] and had completed at least one full course of standardized treatment. The study protocol and reporting were conducted in accordance with the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement [29], and the corresponding checklist is provided in the online supplementary material. This study was approved by the Ethics Committee of Anhui University of Chinese Medicine (Approval No. 2025AH-218). All procedures were performed in accordance with the Declaration of Helsinki. Prior to treatment, medical staff assessed patients’ medical history, treatment compliance, and psychological status. Patients were informed about the physiological mechanisms of normal defecation and received detailed explanations regarding the principles, procedures, and objectives of biofeedback therapy. Written informed consent was obtained from all participants. The choice of treatment strategy was determined by patient preference after physician consultation, ensuring no investigator intervention. To minimize selection bias, the inclusion time window and diagnostic criteria were strictly defined, and all enrolled patients completed at least one standardized course (≥ 10 sessions) under a standardized protocol. Uniform assessment scales and examination methods were applied to ensure data consistency. All data were independently extracted by three investigators, and any discrepancies were resolved by a fourth investigator. Diagnostic criteria [28, 30] The diagnosis of obstructed defecation syndrome (ODS) was established according to the Rome IV criteria for functional gastrointestinal disorders. Patients were required to have a symptom duration of at least 6 months, with the presence of two or more of the following symptoms during the preceding 3 months: straining during defecation in ≥ 25% of bowel movements; hard or lumpy stools in ≥ 25% of bowel movements; sensation of incomplete evacuation in ≥ 25% of bowel movements; sensation of anorectal obstruction or blockage in ≥ 25% of bowel movements; manual maneuvers to facilitate defecation in ≥ 25% of bowel movements; and fewer than three spontaneous bowel movements per week. Based on digital rectal examination and auxiliary diagnostic tests, ODS was further classified into three subtypes: (1) Pelvic floor relaxation type—digital rectal examination revealed decreased anal sphincter tone and weakened contractile strength, with palpable fecal impaction in the rectum. Some patients presented with rectocele or a sensation of mucosal redundancy. Defecography demonstrated findings such as rectocele, internal rectal mucosal prolapse, perineal hernia, anterior rectal wall compression, and low-lying transverse colon. (2) Pelvic floor dyssynergia type—digital rectal examination showed increased anal canal tone with resistance during finger insertion. During simulated defecation, the anal sphincter failed to relax normally or exhibited paradoxical contraction. Defecography revealed features consistent with pelvic floor spasm syndrome, puborectalis syndrome, and internal anal sphincter spasm. (3) Mixed type—patients exhibited combined characteristics of both pelvic floor relaxation and pelvic floor dyssynergia. Inclusion and exclusion criteria Inclusion criteria Patients were eligible for inclusion if they met all of the following criteria: They were aged 18–80 years. They were aged 18–80 years. They had a diagnosis of ODS according to Rome IV criteria. They had a diagnosis of ODS according to Rome IV criteria. They received BFT at our center, either as BFT alone (control group) or electroacupuncture combined with BFT (combination group). They received BFT at our center, either as BFT alone (control group) or electroacupuncture combined with BFT (combination group). They completed ≥ 10 BFT sessions (at least one standardized course). For the combination group, patients were additionally required to receive ≥ 6 EA sessions prior to the prespecified post-treatment assessment as an adjunct to BFT, to avoid exposure misclassification from minimal or occasional EA treatment. They completed ≥ 10 BFT sessions (at least one standardized course). For the combination group, patients were additionally required to receive ≥ 6 EA sessions prior to the prespecified post-treatment assessment as an adjunct to BFT, to avoid exposure misclassification from minimal or occasional EA treatment. Exclusion criteria Patients were excluded if any of the following conditions were present: Concomitant slow transit constipation Concomitant slow transit constipation History of pelvic floor surgery within the past 6 months History of pelvic floor surgery within the past 6 months Implantation of electronic medical devices, such as a cardiac pacemaker Implantation of electronic medical devices, such as a cardiac pacemaker Severe cognitive impairment or psychiatric disorders Severe cognitive impairment or psychiatric disorders Use of opioid medications within the past 6 months Use of opioid medications within the past 6 months Demographic and clinical characteristics The collected variables included age, sex, disease duration, defecography findings, specific diagnostic subtype, and treatment modality. In addition, laxative use before and during treatment was recorded, including whether laxatives were used, the average number of days of laxative use per week, and the type of laxatives. The average number of bowel movements per week was also documented. Pelvic floor surface electromyography was assessed using the Glazer Surface Electromyography Assessment Protocol (Glazer sEMG Protocol), and the following parameters were extracted: mean resting baseline value before contraction, coefficient of variation of the resting baseline, relaxation time after rapid contraction, and coefficient of variation during endurance contraction. Treatment protocols Control group Before treatment, patients’ medical history was reviewed, treatment adherence was assessed, and psychological status was screened. Patients were educated on the physiological mechanisms of normal defecation and received detailed explanations regarding the principles, procedures, and training goals of BFT. All patients in the control group received BFT using a biofeedback stimulation system (Extended-4, Nanjing Vishee Medical Technology Co., China). Each session lasted 30 min and was delivered five times per week; ten sessions constituted one treatment course. In routine practice, BFT is commonly scheduled for up to two standardized courses (20 sessions in total). However, because this was a retrospective study reflecting usual care, not all patients completed the planned schedule; therefore, we reported the distribution of completed sessions. Patients were placed in a relaxed supine position with both legs abducted to hip width. An anal probe electrode was inserted with the second metallic ring positioned 1–2 cm from the anal verge. Two surface electrodes were attached bilaterally over the anterior superior iliac spines, and two abdominal surface training electrode pads were placed 1 cm below the umbilicus with an inter-electrode distance of 1 cm. Each session consisted of two sequential components. First, neuromuscular electrical stimulation (NMES) was delivered for 15 min; stimulation amplitude (current intensity, mA) was titrated from a low level to the maximum tolerable level (below the pain threshold), aiming at eliciting an appropriate pelvic-floor/anal sphincter sensory and/or motor response. Second, sEMG biofeedback training was performed for 15 min. Real-time surface electromyography (sEMG) signals were displayed as visual feedback (e.g., bar graphs, curves, or avatars), and patients were instructed to voluntarily contract and relax the anal sphincter to follow a preset trajectory. The displayed training target/threshold was defined in sEMG amplitude (μV), with an initial target of 10 μV and subsequent adjustment to 15–20 μV according to individual performance. Notably, μV refers to sEMG amplitude used for feedback and training targets rather than electrical stimulation intensity. Treatment group In addition to BFT, patients in the treatment group received electroacupuncture on the same day. All electroacupuncture procedures were performed by licensed acupuncturists who had received standardized training. According to the study protocol, the selected acupoints were divided into an abdominal group [Tianshu (ST25), Daheng (SP15), Qihai (CV6), Fujie (SP14), Zusanli (ST36), and Shangjuxu (ST37)] and a lumbosacral/head group [Dachangshu (BL25), Shenshu (BL23), Zhongliao (BL33), Xialiao (BL34), and Sishencong (EX-HN1)], which were used alternately on different treatment days. ST25, ST36, BL33, and BL34 were selected as the main electrical stimulation points and were needled bilaterally, with the left and right needles connected symmetrically as paired electrodes. Disposable sterile filiform needles (0.25 × 40 mm) were used. ST25, SP15, CV6, and SP14 were inserted perpendicularly to a depth of 0.8–1.2 cun; ST36 and ST37 to 1.0–2.0 cun; BL25 and BL23 perpendicularly or slightly obliquely inward to 0.8–1.2 cun; BL33 and BL34 perpendicularly or obliquely inferomedially to 1.0–1.5 cun; and EX-HN1 subcutaneously to 0.5–0.8 cun. After deqi was obtained, continuous-wave electroacupuncture at 2 Hz was applied for 30 min per session, with the current intensity gradually increased from 1 to 3–5 mA according to patient tolerance. Treatment was administered five times per week for 10 sessions per course, with a minimum frequency of three sessions per week when daily attendance was not feasible. To minimize exposure misclassification due to minimal or occasional EA, patients were required to complete ≥ 6 EA sessions before the prespecified post–10th BFT assessment. The entire treatment process was conducted by the same group of physicians to minimize operator-related bias. Outcome measures Outcome timing “Post-treatment” outcomes were operationally defined as assessments performed after completion of the 10th BFT session and before initiation of the 11th session. When more than one assessment was available within this interval, the record closest to the 10th BFT session was extracted for analysis. Electroacupuncture exposure was quantified as the cumulative number of EA sessions received prior to this prespecified post-treatment assessment. Weekly CSBM responder rate. SBM was defined as a spontaneous bowel movement occurring without rescue laxative use within the preceding 24 h; CSBM was defined as an SBM accompanied by a sensation of complete evacuation. Weekly CSBM responder rate was calculated as the proportion of evaluated patients who met the predefined CSBM responder criteria. A weekly CSBM responder was defined as a patient who achieved ≥ 3 CSBMs per week during treatment and an increase of ≥ 1 CSBM per week compared with baseline [31]. We also clarified the data structure: for each patient, we recorded the mean weekly CSBM frequency during the 2-week pre-treatment baseline observation period, and the mean weekly CSBM frequency during the first 2 weeks of treatment. Because one BFT course consisted of 10 sessions delivered over approximately 2 weeks, the “first 2 weeks of treatment” corresponded to the period up to the prespecified post-10th-session assessment. Constipation Scoring System (CSS) Constipation severity was assessed using the Constipation Scoring System (CSS), which was developed and validated by Agachan et al. [32]. The CSS consists of eight dimensions, including defecation frequency, straining during defecation, and sensation of incomplete evacuation, with a total score ranging from 0 to 30. Higher scores indicate more severe constipation symptoms. The validated Chinese version translated by Liu et al. [33] was used in this study. This version demonstrated good internal consistency (Cronbach’s α = 0.721) and test–retest reliability (intraclass correlation coefficient, ICC = 0.877), indicating satisfactory reliability and validity for assessing constipation severity in the Chinese population. Traditional Chinese Medicine (TCM) syndrome score for constipation Based on the Expert Consensus on Integrated Chinese and Western Medicine Diagnosis and Treatment of Functional Constipation [31], we developed an itemized TCM syndrome scoring sheet for constipation (Supplementary Table S1). The scoring sheet covered constipation-related manifestations, accompanying systemic symptoms, and tongue/pulse signs. Each symptom item was rated on a 4-level severity scale (none, mild, moderate, severe). Main symptoms were scored 0/2/4/6 and secondary symptoms were scored 0/1/2/3. Tongue and pulse signs were assessed as normal vs abnormal; abnormal findings were further graded as major (2 points) or mild (1 point) according to prespecified operational criteria (Supplementary Table S1), whereas normal findings were scored as 0. Higher total scores indicated more severe syndrome manifestations. Patient Assessment of Constipation Quality of Life (PAC-QOL) Quality of life was assessed using the Patient Assessment of Constipation Quality of Life questionnaire (PAC-QOL), which was developed and validated by Marquis et al. [34]. The questionnaire contains 28 items across four domains: physical discomfort, psychosocial discomfort, worries and concerns, and treatment satisfaction, with a total score ranging from 0 to 112. Higher scores indicate poorer quality of life. The validated Chinese version translated by Jin et al. [35] was used in this study. This version showed good internal consistency (Cronbach’s α ranging from 0.82 to 0.94) and test–retest reliability (ICC ranging from 0.75 to 0.93), supporting its reliability and validity in Chinese patients with constipation. Pelvic floor surface electromyography Pelvic floor surface electromyography (sEMG) was measured before and after treatment using a pelvic floor sEMG assessment system (SA9800, Nanjing Vishee Medical Technology Co., China). The following parameters were recorded for both groups: mean resting baseline value, coefficient of variation of the resting baseline, relaxation time after rapid contraction, and coefficient of variation during endurance contraction. Clinical efficacy grading Clinical efficacy was graded according to the TCM syndrome therapeutic efficacy evaluation criteria (efficacy index–based grading). The TCM syndrome efficacy index [31] was calculated as follows: TCM syndrome efficacy index = (TCM syndrome score before treatment − TCM syndrome score after treatment)/(TCM syndrome score before treatment) × 100%. Clinical outcomes were categorized as follows: Cured: efficacy index ≥ 95% Cured: efficacy index ≥ 95% Markedly improved: 70% ≤ efficacy index < 95% Markedly improved: 70% ≤ efficacy index < 95% Improved: 30% ≤ efficacy index < 70% Improved: 30% ≤ efficacy index < 70% Non-responder: efficacy index < 30% Non-responder: efficacy index < 30% Overall response rate was calculated as the proportion of patients classified as improved/markedly improved/cured. Safety outcomes All adverse events (AEs) occurring during treatment and follow-up were recorded, including but not limited to local pain, pelvic floor muscle soreness or spasm, skin burning sensation, rectal bleeding, perianal skin injury, and abnormal changes in bowel movement frequency. Two independent investigators assessed the causal relationship between AEs and treatment according to the International Council for Harmonisation (ICH) E2A guidelines [36], classifying events as unrelated, possibly unrelated, possibly related, probably related, or definitely related. Severity was graded as mild, moderate, or severe according to the Common Terminology Criteria for Adverse Events of the National Cancer Institute [37]. Serious adverse events (SAEs) were defined as events requiring additional medical intervention or resulting in hospitalization and meeting the ICH E2A criteria for seriousness, including death, life-threatening events, or prolonged hospitalization. Study size Because this was a retrospective cohort study, the sample size was determined by the number of eligible patients identified during the study period, and no formal a priori sample size calculation was performed. Statistical analysis Normality of continuous variables was assessed using standard tests. As the variables analyzed were not normally distributed, continuous data are presented as median (interquartile range [IQR]) and categorical data as number (percentage). Between-group comparisons were performed using the Mann–Whitney U test for continuous variables and the chi-square test for categorical variables, as appropriate. Ordinal outcomes were analyzed using an ordinal logistic (proportional-odds) model and are reported as odds ratios (ORs) with 95% confidence intervals (CIs). The ordinal efficacy grade was coded as 0 = non-responder, 1 = improved, 2 = markedly improved, and 3 = cured, with higher values indicating better efficacy; in this model, an OR < 1 indicates lower odds of being in a worse efficacy category. Multivariable linear regression analyses were performed with changes in CSS score, TCM syndrome score for constipation, and PAC-QOL score as dependent variables, and sex, age, disease duration, diagnostic subtype, treatment modality, and laxative use as independent variables. Primary analyses were conducted using an as-treated complete-case approach, including only patients with evaluable baseline data and prespecified post-treatment assessments. No data imputation was performed, and variables with missing values were excluded from the final multivariable models. Because the primary endpoint was assessed after completion of the 10th BFT session and before initiation of the 11th session, conventional long-term loss to follow-up was not applicable to the primary analysis. Given the retrospective observational design, a formal intention-to-treat framework was not applicable. All statistical analyses were two-sided, and P < 0.05 was considered statistically significant. Results Comparison of baseline characteristics between the two groups Baseline characteristics were comparable between groups. There were no significant between-group differences in age, disease duration, days of laxative use before treatment, baseline mean weekly CSBM per patient, sex distribution, diagnostic subtype, baseline laxative use, or baseline surface electromyography parameters (all P > 0.05; Tables 1 and 2). Because the primary post-treatment assessment was anchored after completion of the 10th BFT session and before initiation of the 11th session, both groups had an identical pre-assessment BFT exposure of 10 sessions for the primary analysis. To reflect real-world variation in adherence beyond this standardized assessment point, we additionally reported the distribution of total completed sessions during the treatment period. The median number of completed BFT sessions was 19.5 (IQR 10–20) in the control group and 20 (IQR 10–20) in the treatment group; in the treatment group, the median number of EA sessions was 20 (IQR 10–20). Table 1Comparison of baseline characteristics between the two groups of patients with ODSVariableControl groupTreatment groupMedian (IQR)Median (IQR)Z/χ2P valueAge (years)56.5 (48.25–63)55 (43–62)−1.3730.170Disease duration (years)3 (1–10)4 (1–10)−0.5950.552Days of laxative use per week before treatment5 (3.25–6)5 (5–6)−1.6450.100Mean weekly CSBM per patient before treatment (times)2 (2–3)2 (2–3)−0.2800.779Sex (male/female)39/7357/1270.523Diagnosis (relaxation type/dyssynergia type/mixed type)69/34/9124/40/200.224Laxative use before treatment (no/yes)7/1054/1800.110 Comparison of baseline characteristics between the two groups of patients with ODS Table 2Comparison of clinical efficacy between the two groups of patients with ODSGroupNNon-responders [n (%)]Improved [n (%)]Markedly improved [n (%)]Cured [n (%)]Overall response rate [n (%)]Control group11222 (19.64)79 (70.53)11 (9.82)0 (0)90 (80.36)Treatment group18417 (9.23)109 (59.23)57 (30.98)1 (0.54)167 (90.76)Overall response rate was calculated as the proportion of patients classified as improved/markedly improved/cured Comparison of clinical efficacy between the two groups of patients with ODS Overall response rate was calculated as the proportion of patients classified as improved/markedly improved/cured Comparison of clinical efficacy between the two groups As shown in Table 2, in the treatment group, 1 patient was classified as cured, 57 as markedly improved, 109 as improved, and 17 as non-responders, yielding an overall response rate of 90.76% (167/184). In the control group, 0 patients were cured, 11 were markedly improved, 79 were improved, and 22 were non-responders, with an overall response rate of 80.36% (90/112). The clinical efficacy in the treatment group was significantly superior to that in the control group (P < 0.05). Comparison of primary efficacy outcomes between the two groups As shown in Table 3, the baseline mean weekly CSBM per patient (summarized as median [IQR]) did not differ significantly between the two groups (P > 0.05). At the post-treatment assessment, the mean weekly CSBM increased from baseline in both groups. Weekly CSBM responder rate was significantly higher in the treatment group (90.8%) than in the control group (69.6%) (P < 0.05). Table 3Comparison of main efficacy indicators between the two groups of patients with ODSGroupNMean weekly CSBM per patient before treatment (times)Mean weekly CSBM per patient after treatment (times)Weekly CSBM responder rate after treatment (%)χ2 valueP valueControl group1122 (2–3)4 (4–6)a69.60%21.772<0.001Treatment group1842 (2–3)5 (5–7)a,b90.80%aP < 0.05 vs. baseline in the same groupbP < 0.05 vs. the control group after treatment Comparison of main efficacy indicators between the two groups of patients with ODS aP < 0.05 vs. baseline in the same group bP < 0.05 vs. the control group after treatment Comparison of secondary efficacy outcomes between the two groups As shown in Tables 3 and 4, there were no significant differences in any secondary outcome measures between the two groups at baseline (all P > 0.05). After treatment, both groups showed significant improvements in baseline mean weekly CSBM per patient, average number of days of laxative use per week, CSS score, TCM syndrome score for constipation, quality of life score, and pelvic floor surface electromyography parameters compared with baseline (all P < 0.01). Between-group comparisons demonstrated that the treatment group achieved greater improvements in the increase in average weekly bowel movements and in TCM syndrome score for constipation than the control group (P < 0.05), whereas no significant differences were observed between the two groups in CSS score or quality of life score (P > 0.05). With regard to pelvic floor surface electromyography, the treatment group showed significantly greater improvements in the coefficient of variation of the resting baseline, relaxation time after rapid contraction, and coefficient of variation during endurance contraction compared with the control group (P < 0.05), while no significant difference was found between the two groups in the mean resting baseline value (P > 0.05). Table 4Comparison of secondary efficacy indicators between the two groups of patients with ODSTimeMean weekly days of laxative use (days)CSS score (points)TCM syndrome score for constipation (points)PAC-QOL scores (points)Mean anterior resting baseline (μV)Coefficient of variation of anterior resting baselineRelaxation time after rapid contraction (s)Coefficient of variation of endurance contractionControl groupPre-treatment5 (3.25–6)12 (10–14)23.5 (13–39)64 (53–72.5)2.01 (1.05–3.77)0.99 (0.89–1.29)1.27 (1.24–1.32)1.04 (1.03–1.09)Post-treatment2.5 (1–3)a6 (4–8)a12 (6.25–20)a33.5 (30–39)a1.5 (0.98–2.55)a0.29 (0.28–0.33)a0.46 (0.36–0.48)a0.18 (0.13–0.23)aTreatment groupPre-treatment5 (5–6)12 (10–14)32 (24–39)64 (62–67)2.29 (1.21–3.5)1.02 (0.92–1.19)1.29 (1.23–1.35)1.04 (1.03–1.09)Post-treatment2 (0–3)a,b6 (5–7)a12 (6.25–20)a,b34 (31–39)a1.44 (0.92–2.38)a0.17 (0.16–0.23)a,b0.33 (0.22–0.33)a,b0.12 (0.11–0.14)a,baP < 0.05 vs. baseline in the same groupbP < 0.05 vs. the control group after treatment Comparison of secondary efficacy indicators between the two groups of patients with ODS aP < 0.05 vs. baseline in the same group bP < 0.05 vs. the control group after treatment Multivariate linear regression analysis of score changes in patients with ODS Multivariate linear regression analyses were performed using score changes (post-treatment minus pre-treatment values) as dependent variables, with smaller values indicating greater improvement in symptoms or quality of life. As shown in Table 5, the overall model for changes in CSS score was statistically significant but showed low explanatory power (adjusted R2 = 0.030, P = 0.032). After adjustment for potential confounders, longer disease duration was associated with greater reductions in CSS score after treatment (β = −0.058, P = 0.033). Patients with more frequent prior laxative use also exhibited greater symptom improvement (β = −0.281, P = 0.037). Age (P = 0.064) and the number of days of laxative use during treatment (P = 0.068) showed marginal associations with CSS score changes, whereas no significant effects were observed for the other variables. The model for changes in TCM syndrome score for constipation demonstrated good model fit and the highest explanatory power (adjusted R2 = 0.384, P < 0.001). The main influencing factors were treatment modality and laxative use. Patients in the treatment group showed significantly greater reductions in TCM syndrome score for constipation compared with the control group (β = −7.388, P < 0.001). Patients with prior laxative use also exhibited more pronounced improvements in TCM syndrome score for constipation (β = −10.401, P = 0.001). In contrast, patients who continued to require oral laxatives during treatment showed less symptom improvement, suggesting more refractory disease (β = 11.767, P < 0.001). Other factors, including age, disease duration, and sex, were not significantly associated with changes in TCM syndrome score for constipation. The overall model for changes in PAC-QOL score was marginally significant, with low explanatory power (adjusted R2 = 0.025, P = 0.052). Sex was the only significant predictor, with female patients showing smaller reductions in PAC-QOL scores than male patients, indicating less improvement in quality of life (β = 4.403, P = 0.004). No significant associations were observed for the other variables, including age, disease duration, laxative use, or treatment modality. Table 5Multivariate linear regression analysis of score changes in patients with ODSChange in CSS scoreTCM syndrome score for constipationChange in PAC-QOL scoreβ ± SEP valueβ ± SEP valueβ ± SEP valueAge (years)0.025 ± 0.0130.064−0.041 ± 0.0340.2330.002 ± 0.0520.964Disease duration (years)−0.058 ± 0.0270.033**−0.071 ± 0.070.310−0.035 ± 0.1060.74Weekly days of laxative use before treatment (days)−0.281 ± 0.1340.037**0.026 ± 0.3470.939−0.996 ± 0.5250.059Weekly days of laxative use during treatment (days)0.338 ± 0.1850.068−0.367 ± 0.4780.4430.025 ± 0.7230.972Sex (male = 0, female = 1)0.266 ± 0.3850.491−0.068 ± 0.9950.9454.403 ± 1.5070.004***Treatment regimen (control = 0, treatment = 1)−0.335 ± 0.3760.374−7.388 ± 0.9730.000***−0.315 ± 1.4730.831Laxative use before treatment (no = 0, yes = 1)−0.53 ± 1.1860.655−10.401 ± 3.0640.001***−2.93 ± 4.640.528Laxative use during treatment (no = 0, yes = 1)−0.912 ± 0.6760.17911.767 ± 1.7480.000***0.096 ± 2.6460.971Constant−5.049 ± 1.075−8.169 ± 2.779−23.184 ± 4.208Adjusted R20.0300.3840.025P value0.0320.0000.052Change = post-treatment − baseline∗P < 0.1; ∗∗P < 0.05; ∗∗∗P < 0.01 Multivariate linear regression analysis of score changes in patients with ODS Change = post-treatment − baseline ∗P < 0.1; ∗∗P < 0.05; ∗∗∗P < 0.01 Ordinal multivariate logistic regression analysis of TCM syndrome therapeutic efficacy grades in patients with ODS As shown in Table 6, an ordinal multivariable logistic model was fitted for the ordered clinical efficacy grade, coded in ascending order as 0 = non-responder, 1 = improved, 2 = markedly improved, and 3 = cured (higher values indicate better efficacy). After adjustment for age, disease duration, sex, and baseline laxative use, group assignment remained significantly associated with efficacy grade. Compared with the control group, the treatment group had lower odds of being in a lower (worse) efficacy category (OR = 0.191, 95% CI: 0.106–0.347, P < 0.001), indicating a shift toward better response grades. To improve interpretability, we additionally report model-based predicted probabilities across response grades by arm (Table S2). The predicted probability of non-response was lower in the treatment arm (4.12% vs 20.29%), whereas the probability of “markedly improved” was higher (38.75% vs 10.48%). Laxative use during the treatment period was also strongly associated with poorer efficacy grades (OR = 5.989, 95% CI: 2.303–15.565, P < 0.001). This association should be interpreted as a clinical marker of inadequate symptom control/rescue medication requirement, rather than a causal determinant of suboptimal outcomes, given the likelihood of reverse causation in retrospective data. No statistically significant associations were observed for the remaining covariates (all P > 0.05). Table 6Ordinal multivariate logistic regression analysis of efficacy grades in patients with ODSVariableCodingβSEWaldOR (95%CI)P valueAge (years)Original value0.0090.0100.9781.009 (0.991–1.028)0.243Disease duration (years)Original value−0.0250.0191.6960.975 (0.939–1.013)0.256Weekly days of laxative use before treatment (days)Original value0.0630.0960.4261.065 (0.882–1.284)0.450Weekly days of laxative use during treatment (days)Original value−0.0970.1310.5550.908 (0.703–1.172)0.410SexMale = 0, female = 10.3550.3351.1241.426 (0.74–2.751)0.604Treatment regimenControl = 0, treatment = 1−1.6540.30329.7120.191 (0.106–0.347)0.000***Laxative use before treatment0 = no, 1 = yes−1.3530.8252.6850.258 (0.051–1.303)0.139Laxative use during treatment0 = no, 1 = yes1.790.48813.4735.989 (2.303–15.565)0.000****P < 0.1; **P < 0.05; ***P < 0.01 Ordinal multivariate logistic regression analysis of efficacy grades in patients with ODS *P < 0.1; **P < 0.05; ***P < 0.01 Adverse events No serious adverse events were observed. Mild, self-limited adverse events occurred in 12 patients (6.52%) in the treatment group and 2 patients (1.79%) in the control group; all symptoms resolved spontaneously without additional intervention. Detailed adverse event profiles by arm are summarized in Table 7. Table 7Adverse events during the treatment period by study armAdverse event (patient-level)Control (BFT) (n = 112)Treatment (EA + BFT) (n = 184)Serious adverse events (SAEs)0 (0.00%)0 (0.00%)Any adverse event (overall)2 (1.79%)12 (6.52%)Perianal discomfort or mild heaviness1 (0.89%)3 (1.63%)Soreness/pain at acupuncture sites0 (0.00%)6 (3.26%)Minor subcutaneous bruising/bleeding0 (0.00%)2 (1.09%)Transient dizziness or fatigue0 (0.00%)2 (1.09%)Transient twitching sensation in buttock/groin1 (0.89%)0 (0.00%)Local skin reactions (erythema/edema/electrical marks)0 (0.00%)0 (0.00%)Systemic adverse events (syncope/palpitations, etc.)0 (0.00%)0 (0.00%)(1) Data are presented as number of patients with the event (n (%)). (2) In the treatment group, event categories may overlap (a patient could report more than one symptom); therefore, the sum of individual event counts may exceed the “any adverse event” total. (3) All adverse events were mild and self-limited and resolved spontaneously without additional intervention Adverse events during the treatment period by study arm (1) Data are presented as number of patients with the event (n (%)). (2) In the treatment group, event categories may overlap (a patient could report more than one symptom); therefore, the sum of individual event counts may exceed the “any adverse event” total. (3) All adverse events were mild and self-limited and resolved spontaneously without additional intervention Discussion Biofeedback therapy (BFT), which reinforces appropriate defecation patterns through visual and auditory feedback, is widely recognized as a first-line non-pharmacological treatment for functional defecation disorders. However, its therapeutic efficacy is inconsistent among patients with severe pelvic floor dysfunction (PFD), and a proportion of patients show delayed response or low sensitivity of electromyographic signals during training. Previous studies have reported that approximately 20–40% of patients with PFD respond poorly to BFT alone, highlighting the need for additional or synergistic therapeutic strategies [38]. Consistent with these observations, the present study demonstrated that electroacupuncture combined with BFT was more effective than BFT alone in improving symptoms of ODS. The overall response rate in the treatment group reached 90.76%, which was significantly higher than that in the control group (80.36%). The ordinal multivariate logistic regression analysis showed that, compared with the control group, patients in the treatment group had a significantly lower odds of being in a lower efficacy category (OR = 0.191, P < 0.001), indicating that electroacupuncture combined with biofeedback therapy was more likely to result in higher clinical efficacy. In line with this finding, the multivariate linear regression analysis also demonstrated that the reduction in TCM syndrome score for constipation was significantly greater in the treatment group than in the control group (β = −7.388, P < 0.001), suggesting a superior effect of the combined therapy on symptom improvement in patients with ODS. In the multivariable ordinal model, laxative use during the treatment period was strongly associated with lower (worse) efficacy grades (OR = 5.989, 95% CI: 2.303–15.565, P < 0.001). This finding should be interpreted cautiously: in routine practice, laxatives are often continued or initiated as rescue/adjunctive therapy in response to insufficient symptom improvement, and thus may function primarily as a marker of suboptimal response, with potential reverse causation. Persistent laxative requirement may also reflect greater baseline severity, more refractory defecatory dysfunction, or other unmeasured factors that influence both rescue medication use and treatment outcomes. Prior studies have reported associations between chronic constipation symptom severity and autonomic nervous system imbalance (e.g., reduced parasympathetic activity with relatively increased sympathetic tone), which may contribute to impaired colonic propulsion and altered defecation reflexes [39]. In this context, continued laxative requirement could plausibly reflect a more refractory physiological profile and, consequently, a lower likelihood of achieving optimal response to non-pharmacological interventions; however, causal inferences cannot be made from our retrospective data. Previous studies have shown that electroacupuncture at Tianshu (ST25), Shangjuxu (ST37), and the Baliao points can modulate the enteric nervous system and autonomic nervous system function, thereby promoting colonic propulsive motility and defecation reflexes [26, 40]. Alterations in autonomic nervous system activity can further influence pelvic floor muscle activation patterns during defecation through the gut–brain axis [41]. Compared with changes in absolute muscle strength, autonomic dysregulation may manifest as instability in pelvic floor muscle recruitment and reduced efficiency in the transition between contraction and relaxation. These changes are reflected in surface electromyography as increased variability-related parameters or prolonged relaxation-related time indices, rather than marked changes in mean electromyographic amplitude [42]. In the present study, the coefficient of variation of the resting baseline, the time required for complete relaxation after rapid contraction, and the coefficient of variation during endurance contraction were all significantly lower in the treatment group than in the control group (P < 0.05), whereas no significant difference was observed between the two groups in the mean resting baseline value (P > 0.05). These findings suggest that electroacupuncture combined with biofeedback therapy primarily improves the stability of pelvic floor muscle activity and the coordination of the contraction–relaxation process, rather than simply increasing the overall level of electromyographic activity. It is noteworthy that the present study found that female patients exhibited a smaller improvement in quality of life compared with male patients (β = 4.403, P = 0.004), suggesting that sex may influence the clinical response to electroacupuncture combined with BFT. Previous studies have indicated that women differ significantly from men in terms of obstetric history, hormonal fluctuations, and pelvic floor support structures. These factors may affect pelvic floor functional status and autonomic nervous system regulation, thereby reducing responsiveness to related interventions [43]. Therefore, sex differences may not only reflect variations in anatomical and physiological characteristics, but also indicate differential sensitivity to neuromuscular modulation-based therapies among different patient populations. In addition, in the multivariate linear regression model for changes in CSS score, disease duration remained an independent influencing factor, with longer disease duration being associated with greater reductions in CSS score after treatment (β = −0.058, P = 0.033). Similarly, patients with more frequent prior laxative use also showed more pronounced symptom improvement (β = −0.281, P = 0.037). These findings suggest that long-term symptom burden and repeated pharmacological interventions may influence patients’ response patterns to neuromuscular modulation-based therapies. Previous studies have generally reported that patients with shorter disease duration are more likely to benefit from BFT [44]. The discrepancy between these findings and the results of the present study indicates that the role of disease duration may be heterogeneous across different treatment strategies. Several limitations of this study should be acknowledged. First, this was a single-center retrospective study with a relatively small sample size, and no formal sample size calculation or statistical power analysis was performed. Accordingly, the study may have had limited power to detect between-group differences in some outcomes, particularly those with greater variability, and the possibility of type II error cannot be excluded. Second, information on disease duration and prior laxative use was mainly obtained from medical records, making recall bias unavoidable. Third, some potentially important variables, including obstetric history, pelvic floor structural imaging findings, and hormonal status, were not included in the analysis, which may have resulted in residual confounding and contributed to the relatively low explanatory power of the multivariable models. In addition, because the effectiveness analysis was based on an as-treated complete-case approach rather than a strict intention-to-treat framework, the reported response rates may be susceptible to selection bias and should be interpreted with caution. Furthermore, because outcome assessment was performed at a prespecified short-term post-treatment time point, long-term follow-up data were not available, and the durability of the observed treatment effects could not be determined. Finally, objective assessments of autonomic nervous system function and gut–brain axis-related biomarkers were not included, limiting mechanistic interpretation of the findings. Future prospective studies with larger sample sizes are needed to confirm these results. Overall, in the present cohort, electroacupuncture combined with BFT showed potential advantages over BFT alone in improving several clinical outcomes in patients with ODS, particularly in increasing complete spontaneous bowel movements, reducing constipation severity, and improving quality of life. These findings suggest that adding electroacupuncture to standard BFT may represent a promising complementary therapeutic strategy for ODS. Supplementary Information Below is the link to the electronic supplementary material. (DOCX 34.2 KB) Author contribution W.L. collected clinical data, drafted the main manuscript text, performed statistical analysis and prepared the tables. K.T. and M.L. conceived the study, supervised the project, and revised the manuscript critically. S.L. and Q.Z. collected patient baseline data and assisted in data sorting. All authors reviewed and approved the final manuscript for publication. Funding This study received no external funding. Data availability The data that support the findings of this study are available from the corresponding author upon reasonable request. Declarations Conflict of interest The authors declare no competing interests. Footnotes Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Supplementary Materials (DOCX 34.2 KB) Data Availability Statement The data that support the findings of this study are available from the corresponding author upon reasonable request.